Literature DB >> 20189413

Controversies in defining cardiac antibody-mediated rejection: need for updated criteria.

Abdallah G Kfoury1, M Elizabeth H Hammond.   

Abstract

Recent years have seen a rising awareness of the significance of cardiac antibody-mediated rejection (AMR) as a result of its formal recognition by the International Society for Heart and Lung Transplantation. New insights on the pathology and clinical behavior of cardiac AMR are at odds with current diagnostic guidelines. This perspective examines some of the contentious and unresolved issues in cardiac AMR as the transplant community makes concrete steps towards updating its defining criteria.

Mesh：

Substances：

Year:  2010        PMID： 20189413     DOI： 10.1016/j.healun.2009.10.016

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


  11 in total

Review 1.  [Heart transplantation. Pathology, clinical work-up and therapy].

Authors:  H A Baba; J Wohlschläger; J Stypmann; N E Hiemann
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

2.  Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience.

Authors:  Kevin P Daly; Audrey C Marshall; Julie A Vincent; Warren A Zuckerman; Timothy M Hoffman; Charles E Canter; Elizabeth D Blume; Lisa Bergersen
Journal:  J Heart Lung Transplant       Date:  2011-12-30       Impact factor: 10.247

3.  Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.

Authors:  Dilip S Nath; Nataraju Angaswamy; Haseeb Ilias Basha; Donna Phelan; Nader Moazami; Gregory A Ewald; T Mohanakumar
Journal:  Hum Immunol       Date:  2010-09-21       Impact factor: 2.850

4.  Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.

Authors:  Dilip S Nath; Haseeb Ilias Basha; Venkataswarup Tiriveedhi; Chiraag Alur; Donna Phelan; Gregory A Ewald; Nader Moazami; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2010-07-07       Impact factor: 10.247

Review 5.  Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working Group.

Authors:  Monica R Shah; Randall C Starling; Lisa Schwartz Longacre; Mandeep R Mehra
Journal:  J Am Coll Cardiol       Date:  2012-04-03       Impact factor: 24.094

6.  A role for antibodies to human leukocyte antigens, collagen-V, and K-α1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy.

Authors:  Dilip S Nath; Venkataswarup Tiriveedhi; Haseeb Ilias Basha; Donna Phelan; Nader Moazami; Gregory A Ewald; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2011-05-15       Impact factor: 4.939

7.  Utility of C4d immunostaining in the first year after pediatric and young adult heart transplantation.

Authors:  Ying Xu; Csaba Galambos; Miguel Reyes-Múgica; Susan A Miller; Adriana Zeevi; Steven A Webber; Brian Feingold
Journal:  J Heart Lung Transplant       Date:  2013-01       Impact factor: 10.247

8.  Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.

Authors:  Ashim Aggarwal; Joseph Pyle; John Hamilton; Geetha Bhat
Journal:  Tex Heart Inst J       Date:  2012

9.  Antibody-mediated rejection in heart transplantation: case presentation with a review of current international guidelines.

Authors:  Octavio E Pajaro; Dawn E Jaroszewski; Robert L Scott; Anantharam V Kalya; Henry D Tazelaar; Francisco A Arabia
Journal:  J Transplant       Date:  2011-12-06

Review 10.  Immunologic considerations in heart transplantation for congenital heart disease.

Authors:  Beth D Kaufman; Robert E Shaddy
Journal:  Curr Cardiol Rev       Date:  2011-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.